Skip to main navigation
  Menu

ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
EN
english中文

Investor Relations

Investor Relations

  • Investor Home
  • Corporate Information
  • Stock Information
  • News & Events
  • Financial Information
  • Shareholder Services

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Alerts sign up

Required fields denoted by an asterisk ().
Alert type

About ASLAN

About ASLAN

ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

News Releases
Date Title
Aug 12, 2022
ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 11, 2022
ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress
Jun 07, 2022
ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis
Read More

Investor Relations
E-mail: investor@aslanpharma.com

Shareholder Tools

  • Print Page

    Print Page

  • RSS Feeds

    RSS Feeds

  • E-mail Alerts

    E-mail Alerts

Company

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions

Careers

For more information on employment opportunities at ASLAN, please contact us at careers@aslanpharma.com

Contact Us

Singapore Headquarters
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Tel: +65 6222 4235
Fax: +65 6225 2419

contact@aslanpharma.com